Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.72 +0.30 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
Here's Why Innate Pharma Stock Is Rocketing Higher Today
A clinical trial with an experimental lung cancer drug produced some positive results. 
Via The Motley Fool
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu... 
Via Benzinga
What's Going On With Corvus Pharmaceuticals Stock Today?
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by... 
Via Benzinga
Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.51% to 34,572.50 while the NASDAQ fell 0.78% to 15,062.99. The S&P also fell, dropping 0.72% to 4,441.64. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
From AstraZeneca
Via Business Wire
Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher
Following the market opening Friday, the Dow traded down 0.37% to 34,622.25 while the NASDAQ fell 0.58% to 15,094.19. The S&P also fell, dropping 0.55% to 4,449.03. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
What Is Happening With Innate Pharma Stock On Friday?
Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial... 
Via Benzinga
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Exposures COVID-19
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
From AstraZeneca
Via Business Wire
Mapping The Biggest Companies By Market Cap in 60 Countries
Tech giants are increasingly making up more of the Fortune 500, but the world’s biggest companies by market cap aren’t so cut and dry. 
Via Talk Markets
2 Pharma Stocks You Can Buy and Hold for the Next Decade
Both stocks have grabbed plenty of headlines over the past year. 
Via The Motley Fool
AstraZeneca's Debt Insights
Shares of AstraZeneca (NASDAQ:AZN) decreased by 3.49% in the past three months. Before we understand the importance of debt, let us look at how much debt AstraZeneca has.... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
These Promising Clinical Results Could Be Huge for Amgen Investors
New data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future. 
Via The Motley Fool
UK Preps Up For 'Mix & Match' COVID-19 Booster Program: FT
Citing government sources, the Financial Times reported that the U.K. is potentially preparing to become the first big country to administer a mix and match regime of... 
Via Benzinga
Exposures COVID-19
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings
POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer... 
Via Benzinga
Moderna Shares Gain Amid R&D Day Presentations: What You Need To Know
Moderna, Inc. (NASDAQ: MRNA), a biotech that rose to prominence with its successful coronavirus vaccine program, is holding its fifth annual R&D day Thursday. What Happened:... 
Via Benzinga
Exposures COVID-19
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
From AstraZeneca
Via Business Wire
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
From AstraZeneca
Via Business Wire
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots
The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE: JNJ) and... 
Via Benzinga
Exposures COVID-19
This Med Tech Innovator Just Doubled, And It Can Do It Again
We’re here to crush the market with the foremost innovative tech leaders. 
Via Talk Markets
Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg
Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab
Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication... 
Via Benzinga
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge... 
Via Benzinga
AstraZeneca Enters Another Major Market With This Indication
The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan. 
Via The Motley Fool
Why Innate Pharma Shares Are Rising On Friday?
Innate Pharma SA (NASDAQ:IPHA) stock closed a... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.